New Haven [US], June 6 (ANI): Patients with advanced pancreatic neuroendocrine tumours (NETs) have few treatment options, but researchers at Yale Cancer Center and Yale-New Haven Health's Smilow Cancer Hospital discovered that patients who received a combination of capecitabine and temozolomide had a higher progression-free survival rate than those who received temozolomide alone.
\
\
